3 doses of mRNA Covid vaccines very effective against Omicron, Delta: Study

The study, from the US Centers for Disease Control and Prevention (CDC), found that boosters of mRNA Covid vaccines are 82 per cent effective in protecting against Omicron variant-associated ED visits

Topics
Coronavirus | Coronavirus Vaccine

IANS  |  New York 

Three doses of mRNA Covid-19 vaccines, either Pfizer-BioNTech or Moderna, are effective in protecting against emergency department visits (ED) and hospitalisations associated with Omicron and Delta variations of the virus, claims a new study.

The study, from the US Centers for Disease Control and Prevention (CDC), found that boosters of mRNA Covid vaccines are 82 per cent effective in protecting against Omicron variant-associated ED visits.

It also found that booster shots are 90 per cent effective in protecting against Omicron variant-related hospitalisations.

"Our findings provide important evidence that booster shots are highly effective and those who are unvaccinated are at significantly greater risk of experiencing more severe Covid-19 outcomes and should get vaccinated and boostered as soon as possible," researcher Shaun Grannis from Indiana University, said.

The value of the third dose of an mRNA vaccine is significant as two doses were only 38 per cent effective in protecting against Omicron-related ED visits and only 57 per cent effective in protecting against Covid Omicron variant-related hospitalisations.

Boosters were even more effective against the Delta variant of Covid, protecting against 94 per cent of both Covid Delta variant associated ED visits and hospitalisations.

The CDC collaborated with six US healthcare systems to create the VISION network to assess Covid vaccine effectiveness.

--IANS

vc/sks/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus
First Published: Sat, January 22 2022. 14:40 IST
RECOMMENDED FOR YOU